Evidence map›Paper›PMID 37813418›Full record

Trial reportBMJ (Clinical research ed.)2023

Early versus delayed antihypertensive treatment in patients with acute ischaemic stroke: multicentre, open label, randomised, controlled trial.

Liping Liu, Xuewei Xie, Yuesong Pan, Aili Wang, Yufei Wei, Jingyi Liu, Ximing Nie, Dacheng Liu, Zilin Zhao, Penglian Wang and 19 more

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled TrialMulticenter Study
In one paragraph

Trial report in BMJ (Clinical research ed.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03479554 (China Antihypertensive Trial in Acute Ischemic Stroke II), which is not on this map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03479554 phase3completednot on this map

China Antihypertensive Trial in Acute Ischemic Stroke II

TypeinterventionalSponsorTulane UniversityRan2018 to 2023Enrolled4,810ConditionsAcute Ischemic StrokeArmsEarly antihypertensive treatment, Delayed antihypertensive treatment
3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Blood pressure management for stroke patients beyond the JSH 2025 guidelines.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Observational
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 7 institutions in 2 countries.

Liping LiuDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Xuewei XieDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Yuesong PanDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Aili WangDepartment of Epidemiology, School of Public Health, Suzhou Medical College of Soochow University, Suzhou, China.
Yufei WeiDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Jingyi LiuDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Ximing NieDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Dacheng LiuDepartment of Neurology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Zilin ZhaoDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Penglian WangDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Suwen ShenDepartment of Epidemiology, School of Public Health, Suzhou Medical College of Soochow University, Suzhou, China.
Chongke ZhongDepartment of Epidemiology, School of Public Health, Suzhou Medical College of Soochow University, Suzhou, China.
Tan XuDepartment of Epidemiology, School of Public Health, Suzhou Medical College of Soochow University, Suzhou, China.
Dali WangAffiliated Hospital of North China University of Science and Technology, Tang-shan, China.
Gui-Chun WangChangtu County Hospital, Tieling, China.
Denghua SongSinopharm Tongmei General Hospital, Datong, China.
Yunsheng MaThe First People's Hospital of Keerqin District, Tongliao, China.
Jinguo ZhaoWeihai Wendeng District People' Hospital, Weihai, China.
Yong JiangDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Jing JingDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Xia MengDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Katherine ObstDepartment of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana, USA.
Chung-Shiuan ChenDepartment of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana, USA.
David WangNeurovascular Division, Department of Neurology, Barrow Neurological Institute, St Joseph's Hospital and Medical Center, Phoenix, Arizona, USA.
Yilong WangDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Yonghong ZhangDepartment of Epidemiology, School of Public Health, Suzhou Medical College of Soochow University, Suzhou, China.
Yongjun WangDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Jiang HeDepartment of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana, USA jhe@tulane.edu.ORCID 0000-0002-8286-9652
CATIS-2 Investigators
Capital Medical University · CNSoochow University · CNTulane University · USBarrow Neurological Institute · USChina National Pharmaceutical Group Corporation (China) · CNSecond Affiliated Hospital of Xi'an Jiaotong University · CNThe People's Hospital Tongling · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo compared the effect of early antihypertensive treatment started within 24-48 h of stroke onset versus delaying treatment until day eight on reducing dependency or death.

designMulticentre, randomised, open label trial.

setting106 hospitals in China between 13 June 2018 and 10 July 2022.

participants4810 patients (≥40 years) were enrolled with acute ischaemic stroke within 24-48 h of symptom onset and elevated systolic blood pressure between 140 mm Hg and <220 mm Hg.

interventionsPatients were randomly assigned to receive antihypertensive treatment immediately after randomisation (aimed at reducing systolic blood pressure by 10%-20% within the first 24 h and a mean blood pressure <140/90 mm Hg within seven days) or to discontinue antihypertensive medications for seven days if they were taking them, and then receive treatment on day 8 (aimed at achieving mean blood pressure <140/90 mm Hg).

main outcome measuresThe primary outcome was the combination of functional dependency or death (modified Rankin scale score ≥3) at 90 days. Intention to treat analyses were conducted.

results2413 patients were assigned to the early treatment group and 2397 were assigned to the delayed treatment group. Mean systolic blood pressure was reduced by 9.7% (from 162.9 mm Hg to 146.4 mm Hg) in the early treatment group and by 4.9% (from 162.8 mm Hg to 154.3 mm Hg) in the delayed treatment group within 24 h after randomisation (P for group difference <0.001). Mean systolic blood pressure was 139.1 mm Hg in the early treatment group and 150.9 mm Hg in the delayed treatment group on day seven (P for group difference <0.001). Additionally, 54.6% of patients in the early treatment group and 22.4% in the delayed treatment group had blood pressure of less than 140/90 mm Hg (P<0.001 for group difference) on day seven. At day 90, 289 trial participants (12.0%) in the early treatment group, compared with 250 (10.5%) in the delayed treatment group, had died or experienced a dependency (odds ratio 1.18 (95% confidence interval 0.98 to 1.41), P=0.08). No significant differences in recurrent stroke or adverse events were reported between the two groups.

conclusionsAmong patients with mild-to-moderate acute ischaemic stroke and systolic blood pressure between 140 mm Hg and <220 mm Hg who did not receive intravenous thrombolytic treatment, early antihypertensive treatment did not reduce the odds of dependency or death at 90 days.

trial registrationClinicalTrials.gov Identifier NCT03479554.

Indexed as

Brain IschemiaHypertensionHypotensionIschemic StrokeStrokeAntihypertensive AgentsBlood PressureHumansTreatment OutcomeAntihypertensive Agents

Identifiers

PMID37813418
PMCPMC10561001
OpenAlexW4387461430

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.